Quantisnow Logo
Dashboard

Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

$CGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $CGEN alert in real time by email

HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.  Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.

Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company contact:

Yvonne Naughton, Ph.D.

VP, Head of Investor Relations, and Corporate Communications

Email: ir@cgen.com

Tel: +1 (628) 241-0071 

Cision View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2024-financial-results-on-tuesday-march-4-2025-302378746.html

SOURCE Compugen Ltd.

Get the next $CGEN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CGEN

DatePrice TargetRatingAnalyst
1/13/2025$4.00Outperform
Oppenheimer
8/5/2022$2.00Buy → Hold
Jefferies
2/25/2022$17.00 → $14.00Outperform
Oppenheimer
2/25/2022$16.00 → $9.00Outperform
SVB Leerink
More analyst ratings

$CGEN
 Press Releases

Fastest customizable press release news feed in the world

See more

  • Compugen to Participate in Multiple Virtual Investor Conferences in April 2025

    HOLON, Israel, March 26, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will participate in the following upcoming virtual investor conferences in April 2025: H.C. Wainwright 2nd Annual AI Based Drug Discovery & Development ConferenceDate: Wednesday, April 2, 2025Format: Fireside chat and 1x1 meetingsFireside chat time: 9:30 am ET 24th Annual Needham Virtual Healthcare ConferenceDate: Monday, April 7, 2025Format: Fireside chat and 1x1 meetingsFireside chat time: 8:00 am ET Stifel's 2025 Virtual Targeted Oncology ForumDate: Wednesday, April 9, 2025Form

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • /C O R R E C T I O N -- Compugen Ltd./

    In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Compugen Reports Fourth Quarter and Full Year 2024 Results

    Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combina

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CGEN
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$CGEN
 SEC Filings

See more

$CGEN
 Leadership Updates

Live Leadership Updates

See more

  • Cognyte Elects Two New Board Members to Strengthen Expertise and Drive Growth

    Announcement reflects company's commitment to augment Board of Directors with industry-experienced executives from both the government and software sectors Cognyte Software Ltd. (NASDAQ:CGNT) ("Cognyte"), a global leader in investigative analytics software, today announced the appointment of two new members to its Board of Directors. Matthew O'Neill and Nurit Benjamini will join the board on March 1, 2025, and March 31, 2025, respectively, reflecting the company's commitment to add independent directors from the government and software sectors. Richard Nottenburg will be stepping down from his board position effective March 31, 2025. Having served with the United States Secret Service f

    $ALLT
    $BLRX
    $CGEN
    $CGNT
    Computer Communications Equipment
    Telecommunications
    Biotechnology: Pharmaceutical Preparations
    Health Care

  • Compugen Appoints David Silberman as Chief Financial Officer

    HOLON, Israel, May 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of David Silberman as its new Chief Financial Officer effective August 15, 2024, taking over from Alberto Sessa who will depart Compugen on the same day. David will join Compugen from Oramed Pharmaceuticals Inc., where he served as Chief Financial Officer. "I am excited to welcome David to Compugen and believe his experience and insights will make him a pivotal additio

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer

    HOLON, Israel, Feb. 15, 2024 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced the appointment of Michelle Mahler, M.D., as Chief Medical Officer, effective March 1, 2024. Michelle will succeed Henry Adewoye, M.D., who is leaving Compugen to pursue other opportunities effective February 29, 2024, after 6 years with Compugen. "I am delighted that Michelle will join the management team as Chief Medical Officer at a very exciting time for Compugen," said Anat Coh

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CGEN
 Financials

Live finance-specific insights

See more

  • /C O R R E C T I O N -- Compugen Ltd./

    In the news release, Compugen Reports Fourth Quarter and Full Year 2024 Results, issued 04-Mar-2025 by Compugen Ltd. over PR Newswire, in the Conference Call and Webcast Information section, the link to the webcast should be "https://veidan.activetrail.biz/compugenq4-2024". The complete, corrected release follows: Compugen Reports Fourth Quarter and Full Year 2024 Results Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Compugen Reports Fourth Quarter and Full Year 2024 Results

    Clinical data presented at SITC 2024 supports further development of COM701, potential first-in-class anti-PVRIG antibodyOn track to initiate a randomized adaptive platform trial of COM701 maintenance therapy in patients with platinum sensitive ovarian cancer, scheduled to start in Q2 2025The first patient was dosed in Q1 2025 in the first in human Phase 1 solid tumor trial of GS-0321 (previously COM503), a potential first-in-class anti-IL18BP antibody licensed to GileadPartner AstraZeneca reported promising rilvegostomig data in 2024, expanded the rilvegostomig program to seven Phase 3 trials across lung and gastrointestinal cancers and plans to share early data for rilvegostomig in combina

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

  • Compugen to Release Fourth Quarter and Full Year 2024 Financial Results on Tuesday, March 4, 2025

    HOLON, Israel, Feb. 18, 2025 /PRNewswire/ -- Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced, that it will release its fourth quarter and full year 2024 financial results on Tuesday, March 4, 2025, before the U.S. financial markets open.  Management will host a conference call and webcast to review the financial results and provide a corporate update at 8:30 am ET. To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following lin

    $CGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$CGEN
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more